Helping patients save on biomarker testing*

Click on the appropriate box below to learn more about financial support options associated with comprehensive biomarker testing, including KRAS G12C testing for patients diagnosed with stage IV metastatic non-small cell lung cancer (NSCLC)*

KRAS= Kirsten Rat Sarcoma

*Program limitations apply, please see terms and conditions including limits on individual program coverages. Programs valid for testing performed through December 31, 2022.